Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
Operator: Hello and welcome to the Halozyme Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,724,811 | $104,087,780 | +18% | 0.21% |
| 2. | 47,871,000 | $44,845,237 | 0% | ||
| 3. | 50,000,000 | $42,190,000 | -4% | 0.66% | |
| 4. | Millennium Management Israel Englander | 901,445 | $34,435,199 | -51% | 0.01% |
| 5. | Driehaus Capital Richard Driehaus | 520,776 | $19,893,643 | +1% | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | Director | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | Director | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | Director | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.79 | 10,000 | 151,911 | 2023-11-15 | Filing | ||
| $39.08 | 1,708 | 151,911 | 2023-11-14 | Filing | ||
| $39.08 | 8,292 | 151,911 | 2023-11-14 | Filing | ||
| $36.52 | 10,000 | 151,911 | 2023-10-17 | Filing | ||
| $39.10 | 10,000 | 151,911 | 2023-09-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,118,615 | $692,131,092 | 0.01% | |
| 2. | 13,106,644 | $500,673,801 | 0.01% | |
| 3. | 7,712,874 | $294,631,787 | 0.49% | |
| 4. | 6,209,531 | $237,204,084 | 0.01% | |
| 5. | 4,324,232 | $165,185,662 | 3.72% |
News See All
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
Should You Remain Confident in Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, my name is Chris and I'll be your conference operator today.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
15 Best Russell 2000 Stocks To Buy Now
In this article, we discuss 15 best Russell 2000 stocks to buy.
Should You Hold Halozyme Therapeutics (HALO)?
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Here’s Why Halozyme Therapeutics (HALO) Declined in Q1
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, my name is Chris and I'll be your conference operator today.
Halozyme Therapeutics (HALO) Declined on 2023 Profit Outlook
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first-quarter 2023 investor letter, a copy of which can be downloaded here.
Billionaire Hedge Funds
